Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Peet M1, Brind J, Ramchand CN, Shah S, Vankar GK.

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Peet M1, Brind J, Ramchand CN, Shah S, Vankar GK.
Academic Department of Psychiatry, Northern General Hospital, The Longley Centre, Norwood Grange Drive, S5 7JT, Sheffield, UK. m.peet@sheffield.ac.uk
Abstract
Evidence that the metabolism of phospholipids and polyunsaturated fatty acids (PUFA) is abnormal in schizophrenia provided the rationale for intervention studies using PUFA supplementation. An initial open label study indicating efficacy for n-3 PUFA in schizophrenia led to two small double-blind pilot studies. The first study was designed to distinguish between the possible effects of two different n-3 PUFA: eicosapentaenoic acid (EPA) and docohexaenoic acid (DHA). Forty-five schizophrenic patients on stable antipsychotic medication who were still symptomatic were treated with either EPA, DHA or placebo for 3 months. Improvement on EPA measured by the Positive and Negative Syndrome Scale (PANSS) was statistically superior to both DHA and placebo using changes in percentage scores on the total PANSS. EPA was significantly superior to DHA for positive symptoms using ANOVA for repeated measures. In the second placebo-controlled study, EPA was used as a sole treatment, though the use of antipsychotic drugs was still permitted if this was clinically imperative. By the end of the study, all 12 patients on placebo, but only eight out of 14 patients on EPA, were taking antipsychotic drugs. Despite this, patients taking EPA had significantly lower scores on the PANSS rating scale by the end of the study. It is concluded that EPA may represent a new treatment approach to schizophrenia, and this requires investigation by large-scale placebo-controlled trials.

Related posts:

  1. Omega 3 EPA Fish Oil Shows Procognitive Effects in Schizophrenia
  2. Meta-analysis of the effects of omega 3 fish oil eicosapentaenoic acid (EPA) in clinical trials in depression.
  3. Increased blood levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) may reduce the severity of symptoms of depression, particularly in people taking antidepressants
  4. Research shows effectiveness of a daily dose 2.5G omega3 re treatment of depression in elderly
  5. Omega3 fish oil EPA as effective as Prozac in the treatment of medium to major depression

Leave a Reply

Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...